NAPANEE, Ontario, May 23, 2018 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSX-V:ABCN)
(“ABcann” or the “Company”) is pleased to announce the launch of Beacon Medical, its new medical
cannabis brand. The goal of Beacon Medical is to help patients and their healthcare providers navigate the complex
medical cannabis market to find the best treatment option.
“Our vision is to leverage our unique experience in the global pharmaceutical industry to create one of
the most respected medical cannabis companies. The launch of Beacon is an important step towards that vision,” stated Barry
Fishman, Chief Executive Officer.
The adoption of the Beacon Medical brand is a direct result of an exclusive study of 1,500 Canadians that ABcann
conducted in early 2018. The Company is committed to developing its brands based on deep consumer insights. ABcann’s study
identified that 73% of adult Canadians who are not currently using cannabis, but have a treatable condition, say they lack the
appropriate knowledge of how to use medical cannabis, and 67% say they are unfamiliar with how to obtain medical cannabis. With so
many Canadians not clear about how to obtain and use medical cannabis, ABcann believes the market is ready for a brand that makes
the process easier to navigate.
Beacon Medical will differentiate itself by focusing on the patient experience: simple registration and product
classification, efficient purchasing, pharmaceutical-grade products, and compassionate customer service.
“A beacon is a symbol of hope and relief for those seeking guidance, and that’s why Beacon is a perfect
metaphor and the ideal name for our new medical cannabis brand. We want to develop simple ways to help people navigate the complex
world of cannabis,” stated Sung Kang, Chief Marketing Officer.
Beacon Medical invites investors, media and consumers to get a first glimpse of the new Beacon brand at the Lift
Expo taking place in Toronto from May 25th to 27th, 2018. The full Beacon Medical website and product line,
which will include the introduction of cannabis oils, will be available to ACMPR patients by early summer 2018.
About ABcann
ABcann is recognized for high-quality, trusted products and services. It holds production and sales licenses
from Health Canada, and its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its
specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade
cannabis products. ABcann is expanding its production capacity and pursuing partnership and product development opportunities
domestically, as well as in select international markets, such as Germany, Australia and Israel.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this news release may be considered forward-looking statements, which are statements that
are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of ABcann and its
management regarding the future. Forward-looking statements in this news release include statements relating to: the expected
legalization of the adult-use cannabis market; the expected launch time of the Beacon Medical product line and website; the
expected impact of the Beacon Medical brand on the market; the Beacon Medical product line including cannabis oils; and ABcann’s
goal of becoming one of the best and most respected medical cannabis business in Canada and internationally. Such statements are
subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those
contained in the forward-looking statements, including the possibility that ABcann may not derive the expected benefits from the
adoption of the Beacon Medical brand; that the market will not adopt the Beacon Medical brand; that the differentiating factors
between the Beacon Medical product line and those of ABcann’s competitors will not materialize; that the adult-use market will not
open as expected; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by
the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged
to consider these factors, and the more extensive risk factors included in the Company’s annual information form dated April 30,
2018, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are
cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary
statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent
or obligation to update publicly any such forward-looking statements, whether because of new information, future events or results
or otherwise, except as required by applicable securities laws.
For more information about ABcann, please contact: Barry Fishman at barry.fishman@abcannglobal.com or Michael Bumby at michael.bumby@abcannglobal.com
